ICPE EXHIBITORS AND SPONSORS

The International Society for Pharmacoepidemiology (ISPE) gratefully acknowledges the generous support of the following organizations and institutions. Their contributions and memberships helped to enhance the scientific program content and increase attendance at the ICPE 2006. Thank you.

EXHIBITORS
Charles River Laboratories Clinical Services
DrugLogic
GlaxoSmithKline
GPRD
i3 Drug Safety
IPCI Erasmus University Medical Center
John Wiley & Sons
MedTel Outcomes, LLC
PharmIdeas Research
PHARMO Institute
Phase Forward/Lincoln Technologies
RTI Health Solutions
Sentrx
Uniform Data System
United BioSource Corporation
The Uppsala Monitoring Centre
Wolters Kluwer Health, Adis

ACADEMIC SHOWCASE / WELCOME RECEPTION SPONSORS
Boston Collaborative Drug Surveillance Program, Boston University
Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
Drug Safety Research Unit
Pharmacoepidemiology and Therapeutics Program, Utrecht Institute for Pharmaceutical Sciences (UIPS)
Pharmacy Practice & Administration Division, College of Pharmacy, University of Texas at Austin
Slone Epidemiology Center, Boston University
The Pharmaceutical Health Services Research Graduate Program at the University of Maryland, Baltimore School of Pharmacy

ANNUAL MEETING SPONSORS

DIAMOND: $25,000
- i3 Drug Safety

PLATINUM: $12,000
- John Wiley & Sons
- Novartis
- Pfizer

GOLD: $6,000
- Amgen
- Eli Lilly and Company
- GlaxoSmithKline
- Merck & Co., Inc. — USA
- RTI Health Solutions
- Procter & Gamble
- United BioSource Corporation
- Wyeth Research

SILVER: $3,000
- Boehringer Ingelheim Pharmaceuticals
- Genzyme

BRONZE: $1,500
- Allergan
- GPRD
- HealthCore
- Outcome

IN THIS PROGRAM:

22nd ICPE Agenda
Wednesday..............................................7
Thursday...................................................8
Friday.....................................................9
Saturday................................................16
Sunday..................................................24

22nd ICPE Posters
Poster Presentation Guidelines..................30
Poster Session A..........................................31
Poster Session B..........................................39
Poster Session C..........................................45

22nd ICPE Abstract Index
Abstract Index...........................................52
AGENDA | Wednesday, August 23

11:00–Noon
- ISPE Finance Committee (Hotel Vila Gale Opera)

Noon–1:00PM
- Orientation Session for New ISPE Board Members (Hotel Vila Gale Opera)

Noon–5:30PM
- Registration (Registration Desk/Ground Floor/Congress Centre)

1:00–5:30PM
- ISPE Board of Directors Meeting (Hotel Vila Gale Opera)

PRE-CONFERENCE EDUCATIONAL SESSION

1:30–5:30PM
- Speakers Ready Room/AV (Rooms 1.09 + 1.14)
- Introduction to Pharmacoepidemiology (AUD 3 & 4)
  Registration required; included as part of full meeting registration.
  Chair: Andrew McAfee
  Andrew Bate, Spontaneous Reporting
  Andrew McAfee, Cohort Studies
  Michael Lewis, FISPE, Case-Control Studies
  Jacques LeLorier, FISPE, Confounding by Indication

7:30–10:00PM
- ISPE Board of Directors Dinner (By invitation)

Badges
All attendees at ICPE 2006 must wear their name badges to all events. A badge will be needed for admission to meeting related functions such as scientific sessions, the exhibit/poster hall, and social events. Badges will be included in the registration packet material. In some cases, tickets will be required.

Badge Legend
- Student – Yellow
- New Member – Blue Dot
- One Day Attendee – Red

Room Legend
- AUD = Auditorium
- PAV = Pavilion

FUTURE MEETINGS

2006
- First Asian International Society for Pharmacoepidemiology Conference combined with the Third China Shanghai International Conference on Rational Drug Use and Pharmacoepidemiology
- September 26–29, 2006
- Shanghai & Lu Mountain, Jiangxi province, China

2007
- ISPE Mid-Year Meeting
  - April 21–22, 2007
  - Hotel NH Grand Hotel Krasnapolsky
  - Amsterdam, The Netherlands
  - (Meeting held in conjunction with the Pharmaceutical Sciences World Congress)
  - Saturday, April 21
    - 8:30–12:30pm Introduction to Pharmacoepidemiology
    - 12:30–5:30pm ISPE Board of Directors Meeting
  - Sunday, April 22
    - 8:30–13:00pm Advanced Topics in Pharmacoepidemiology
    - 1:30–5:30pm ISPE Scientific Program Committee –2007
  - Monday, April 23
    - ISPE Contributed Symposium at the PSWC
    - RAI Congress Centre
    - www.fip.org/PSWC

2008
- ISPE Mid-Year Meeting
  - April TBD, 2008
  - Boston, Massachusetts, USA

2009
- ISPE Mid-Year Meeting
  - April, TBD
  - Copenhagen, Denmark

2010
- ISPE Mid-Year Meeting
  - April, TBD
  - Stockholm, Sweden

2011
- ISPE Mid-Year Meeting
  - April, TBD
  - Providence, Rhode Island, USA
AGENDA | Thursday, August 24

8:00-6:00PM
❖ Registration (Registration Desk/Ground Floor/Congress Centre)

8:00-5:00PM
❖ Speakers Ready Room/AV (Rooms 1.09 + 1.14)

PRE-CONFERENCE EDUCATIONAL SESSIONS

8:30-Noon
❖ Introduction to Therapeutic Risk Management: Evaluating the Effectiveness of Risk Management Programs (AUD 3 & 4)
  * Admission by ticket only. Tickets will be included in registration for those who registered for this session.

  Elizabeth Andrews, FISPE, Overview of Risk Management and the Role of Evaluation
  Javier Cid, Selected Examples of Risk Management Programs and Evaluation
  Judith Jones, FISPE, Workshop for Participants to Develop an Evaluation Plan

8:30 - Noon
❖ Skills Workshop – Students Only* (Room 3A)
  * Registration required; included as part of full meeting registration

  • How to Design an Effective Presentation for Your Internal and External Stakeholders [649]
    Shubh L Sethi, Matthew W Reynolds. (United States)

  • How Did I Get Here?
    Roundtable discussion of career opportunities within pharmacoepidemiology
    Moderator: Marieke Schoonen
    Panelists:
    Peter Egger, European Industry Perspective
    Tjeerd van Staa, European Regulatory Agency Perspective
    Stephen J. Evans, Academic Perspective
    TBA, Consulting Perspective

Noon – 1:30PM
❖ Lunch – on your own (available at Congress Centre)

Noon-1:30PM
❖ ISPE Education Committee (Room 1.05)

Noon-1:30PM
❖ Orientation to ISPE – New Members/Student Prize Winners/ Scholarship Recipients (Espaço Tejo Restaurant/First Floor/Congress Centre)

Noon – 5:00PM
❖ Exhibitor Move-in (PAV 5)

PRE-CONFERENCE EDUCATIONAL SESSION

1:30-5:30PM
❖ Advanced Topics in Pharmacoepidemiology (AUD 3 & 4)
  * Admission by ticket only. Tickets will be included in registration packet for those who registered for this session.

  Chair: Sebastian Schneeweiss, FISPE
  Larry Lynd, Methods in Quantitative Benefit-Risk Assessment
  June Raine, Use of Pharmacoepidemiologic Data in Regulatory Decision Making
  John Ioannidis, Meta-Analysis of Studies on the Safety of Medications
  Julia Kirchheiner, CYP Polymorphisms and Implications for Pharmacoepidemiology

5:00-6:00PM
❖ Academic Showcase Set-up
  (Foyer - First Floor)

6:30-8:00PM
❖ Academic Showcase/
  Welcome Reception (Foyer – First Floor)
  Admission by badge or ticket. Cash bar

  • Welcome
    Ana Paula Martins, Local Host Committee
    Bert Leufkens, FISPE, Chair, Scientific Program Committee
    Sean Hennessy, FISPE, ISPE President

  • Academic Programs (as of July 25, 2006)
    Boston Collaborative Drug Surveillance Program,
    Boston University School of Medicine
    Center for Clinical Epidemiology & Biostatistics,
    University of Pennsylvania School of Medicine
    College of Pharmacy, University of Texas
    Drug Safety Research Unit
    Pharmacoepidemiology and Therapeutics Program,
    Utrecht Institute for Pharmaceutical Sciences (UIPS), University of Utrecht
    Slone Epidemiology Center, Boston University
    The Pharmaceutical Health Services Research Graduate Program at the University of Maryland, Baltimore School of Pharmacy
AGENDA | Friday, August 25

8:00-9:00AM
- Poster Session A Set-up (PAV 4)

8:00-5:00PM
- Exhibits (PAV 5)
- Speakers Ready Room/AV (Rooms 1.09 + 1.14)

8:00-6:00PM
- Registration
  (Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM
- OPENING SESSION (AUD 1)
  - Welcome
    Bert Leufkens, FISPE, Chair, Scientific Program Committee
    Vasco de Jesus Maria, Chair, Local Host Committee
  - Presidential Address
    Sean Hennessy, FISPE, ISPE President
  - Keynote Address
    Richard Laing, WHO Department of Policy and Standards for Medicines, Geneva Switzerland
    Pharmacoepidemiology for Public Health

10:30-11:00AM
- Break/Posters/Exhibits (PAV 4/5)
  Sponsored by RTI Health Solutions

---

Pharmacoepidemiology for Public Health

---

THE DATABASE CHALLENGE

Rely on our experience to select the right databases for your epidemiological studies.

Contact
Research Triangle Park, NC, USA
US 1.800.262.3011/1.919.541.6000 x1541
Manchester, UK
UK 44((0)161.232.3400
www.rtihsa.org
rtihealthsolutions@rti.org

Visit RTI Health Solutions’ exhibit booth to learn how we can help you design and implement your database studies.
Test your knowledge of European databases and win a prize.
LEADING RESEARCH...
MEASURES THAT COUNT
11:00–12:30PM

CONCURRENT SESSIONS

 риск оценки: вкладываемые публикации (AUD 2)

Модераторы: Byung-Joo Park, FISPE & Corinne de Vries

11:00AM

Стероиды кортикоидов и риск атриовентрикулярной фибрилиации [2]
Cornelis S van der Hoof, Jan Heeringa, Guy G Brusselle, Albert Hofman, Jacqueline C Witterman, Herre Kingma, Miriam C Sturkenboom, Bruno H Stricker. (Netherlands)

11:15AM

Увеличение риска конечной стадии почечной недостаточности, связанное с прописанием китайских травяных средств: Обзор представительной группы 200,000 человек в Тайване, 1997-2002 [3]
Ming-Nan Lai, Jung-Nien Lai, Pau-Chung Chen, Wei-Lum Tseng, Ya-Yin Chen, Jung-Der Wang. (Taiwan)

11:30AM

Mark L Ma, Meng Tan, Kenneth Hornbuckle. (United States)

11:45AM

Ангиотенсин конвертинг энзим – ингибиторы и ангиотенсин II рецептор антагонисты и риск острового панкреатита: популяционный случай-контрольный анализ [5]
Christiane Gasse, Jacob Jacobsen, Mette Nørgaard, Henrik T Sørensen, Søren P Johnsen. (Denmark)

12:00PM

Оральный глюкокортикоиды и риск самоубийства. Сводный анализ из общей практики исследовательского данных [6]
Patrick C Souverein, Niels Speksnijder, Tjeerd P van Staa, Berend Olivier, Toine CG Egberts, Hubert GM Leufkens. (Netherlands)

12:15PM

Препараты бета-блокеров у пациентов с передовой неудовлетворительной сердечной фракцией: Импульсы для выживаемости [7]
Daniela Dobre, Dirk J Van Veldhuizen, Mike JL Delongste, Carolein Lucas, Ger Cleuren, Robbert Sanderman, Adelta V Ranchor, Flora M Haaijer-Ruskamp. (Netherlands)

SYMPOSIUM: Methods of Therapeutic Benefit-Risk Assessment [1] (AUD 1)
Y Moride, L Lynd, L Abenhaim, N Moore, X Kurz, C Hartford. (Canada)

WORKSHOP: Prescribing Quality Indicators Based on Administrative Data: Grasping the Essence or Scratching the Surface? [20] (AUD 3)
B Wettermark, M Andersen, V Vlahovic-Palcevski, R Vander Stichele, F Haaijer-Ruskamp, P Mol. (Netherlands)

WORKSHOP: Designed Delays vs Rigorous Pragmatic Trials: How Much Should We Allow the Gold Standard of Evidence To Be Tarnished? [21] (AUD 4)
Malcolm Macleure, Colin Dormuth, Sebastian Schneeweiss, Tom MacDonald. (United States)
Birth Defects: Contributed Papers (AUD 6)

Moderators: Abraham Hartzema, FISPE & Filipa Costa

11:00AM
Late Pregnancy Use of Non-Steroidal Anti-Inflammatory Drugs and Risk for Persistent Pulmonary Hypertension of the Newborn [8]
Sonia Hernández-Díaz, Martha M Werler, Carol Louik, Linda J Van Marter, Allen A Mitchell. (United States)

11:15AM
Risk of Congenital Malformations in Pregnant Users of Non-Steroidal Anti-Inflammatory Drugs [9]
Benjamin D Ofori, Driss Oraichi, Anick Berard. (Canada)

11:30AM
Exposure to Mirtazapine during Pregnancy: A Prospective Comparative Study of Birth Outcomes [10]
Josephine Djulus, Gideon Koren, Thomas Einarson, Lynda Wilton, Saad Shakir, Orna Diav-Citrin, Deborah Kennedy, Sharon Lavigne, Marco De Santis, Adrienne Einarson. (Canada)

11:45AM
Increase of Antidepressants’ Use in Pregnancy in the Netherlands [11]
Marian K Bakker, Paul B van den Berg, Pieternel Kolling, Lolkje TW de Jong-van den Berg. (Netherlands)

12:00PM
Paroxetine in the First Trimester of Pregnancy and the Prevalence of Congenital Malformations [12]
J Alexander Cole, Eva W Ng, Sara A Ephross, Irene S Cosmatos, Alexander M Walker. (United States)

12:15PM
Antibiotics Potentially Used in Response to Bioterrorism and Major Congenital Malformations [13]
William O Cooper, Sonia Hernández-Díaz, Patrick G Arbogast, Wayne A Ray. (United States)

Respiratory Outcomes: Contributed Papers (AUD 8)

Moderators: Jose Marinho Falcao & Keith Beard, FIPSE

11:00AM
Annual Influenza Vaccination in Community Dwelling Elderly and the Risk of Lower Respiratory Tract Infections or Pneumonia [14]
Bettie CG Voordouw, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

11:15AM
The Control and Severity of Asthma during Pregnancy and the Incidence of Asthma in the Offspring [15]
Marie-Josee Martel, Evelyne Rey, Marie-France Beauchesne, Jean-Luc Malo, Sylvie Perreault, Amelie Forget, Lucie Blais. (Canada)

11:30AM
Assessing the Time–Dependency Nature of Comorbidity Influence in COPD [16]
Victor A Kiri, James Oyee. (United Kingdom)

11:45AM
Effectiveness of Combination Therapy in Asthma [17]
Lucie Blais, Catherine Lemière, Claudine Marcou, Sylvie Perreault, Djamal Berbiche. (Canada)

12:00PM
Use of beta–2 Agonists and Risk of Hip/Femure Fracture: Associations with Daily and Cumulative Dose in a Population-Based Case-Control Study [18]
Frank de Vries, Sander Poulwes, Madelon Bracke, Jan-Willem Lammers, Bert Leufkens, Mira Zuidgeest, Tjeerd van Staai. (Netherlands)

12:15PM
Theophyllins, Long-Acting b2-Agonists and Inhaled Corticosteroids and the Risk of Mortality among Patients with Chronic Obstructive Pulmonary Disease [19]
Marie-Christyne Cyr, Marie-France Beauchesne, Catherine Lemière, Lucie Blais. (Canada)
AGENDA | Friday, August 25

12:30 - 2:00PM

- Lunch/Poster Session A/Exhibits (PAW 4/5)
- EuroDURG General Assembly (AUD 2)
- ISPE Committee/Council Meetings

Lunches will be available in meeting rooms.
*Open to all participants.

- Public Policy Committee (Room 1.08)
- Student Council (Room 1.07) *All students invited to attend.
- Public Relations Committee (Room 1.06)
- Bylaws & Policies Committee (Room 1.05)
- Fellowship & Awards Committee (Room 1.04)

2:00 - 3:30PM

CONCURRENT SESSIONS

- SYMPOSIUM: Control of Unmeasured Confounding [22]
  (AUD 1)
  Til Stürmer, Jay S Kaufman, Alan Brookhart, Michal Abrahamovicz, Robert J Glynn, Kenneth J Rothman. (United States)

- Risk Management: Contributed Papers (AUD 2)
  Moderators: Stephen J.W. Evans & Priya Bahri
  
  2:00PM
  Adverse Drug Reactions in Children: A Multicenter Study in Italy [23]
  Francesca Menniti-Ippolito, Roberto Da Cas, Monica Boli, Annalisa Capuano, Giuseppe Traversa. The Multicenter Study Group on Adverse Drug Reactions in Children. (Italy)

  2:15PM
  Prenatal Testing Prior to Enrollment in Pregnancy Exposure Registries [24]
  Susan Roberts, Deborah Covington, Peggy Doi. (United States)

  2:30PM
  An Evaluation of a Sticker-Based RMP for Isotretinoin [25]
  Carla M Van Bennekom, Allen A Mitchell. (United States)

  2:45PM
  No Increased Risk of Abdominal or Pelvic Surgery Associated with Tegaserod Exposure: The Zelnorm™ Epidemiological Study [26]
  John D Seeger, Sherry Quinn, Fabio Lievano, Elena Rivero, David L Earnest, Michael Shetzline, William Holden, Alexander M Walker. (United States)

  3:00PM
  Safety-Related Drug Labeling Changes in the United States and Germany [27]
  Edeltraut Garbe, René Schade, Frank Andersohn. (Germany)

  3:15PM
  Does Risk Communication Have a Direct Impact in the Overall Pharmacovigilance Activities? [28]
  M Arriegas, F Bragança, R Carmona, A Pêgo, P Roque, J Silva, I Sobral. (Portugal)

  Nicholas D Moore, Elisabeth Loupi, Brian Edwards, Kees VanGrootheest. (France)

- Workshop: Methodologies and Platforms for Policy Evaluation of Pharmaceutical Interventions [42] (AUD 4)
  Pieter Stolk, Sebastian Schnneewiss, Robert H Vander Stichele, Eibert R Heerdink. (Netherlands)
Psychotropics in Children: Contributed Papers (AUD 6)
Moderators: Adrienne Einarson & Emilio Sanz

2:00PM
Psychotropic Medication Use among Publicly Insured U.S. Youth [29]

2:15PM
Sengwee Toh. (United States)
* Student Award – Best Drug Utilization Abstract

2:30PM
Drug Utilization Study of Methylphenidate, Dexamfetamine and Atomoxetine in Patients Aged 15-21 Years in UK Primary Care Using the General Practice Research Database (GPRD) [31]
Suzanne McCarthy, Macey Murray, Ian Wong. (United Kingdom)

2:45PM
Stimulant Utilization in Children and Adolescents in 4 Countries [32]
Julie M Zito, Daniel J Safer, Lolkje TW de Jong-vandenBerg, Jorg M Fegert, Katrin Janhsen, Corinne S de Vries, Gerd Glaeske. (United States)

3:00PM
Effect of Government Regulatory Changes on SSRI Prescriptions in Children [33]
Benji T Kurian, Patrick G Arboast, Wayne A Ray, DC Fuchs, William O Cooper. (United States)

3:15PM
Antidepressant Use among Children and Adolescent in Finland: A Register-Linkage Study, 1994-2003 [34]
Sinikka Silvo, Tiina Sevon, Jari Haukka, Elina Hemminki, Ilmo Keskimaki, Sonja Lumme, Alison McCallum, Kristian Wahlebeck. (Finland)

Genes and Biologicals: Contributed Papers (AUD 8)
Moderators: Henrique de Barros & Joanna F. Haas

2:00PM
Diuretic-Gene Interactions and the Risk of Myocardial Infarction and Stroke [35]
Hedi Schelleman, Olaf H Klungel, Jacqueline CM Witteman, Cornelia M van Duin, Albert Hofman, Monique MB Breteler, Anthonius de Boer, Bruno HCh Stricker. (Netherlands)

2:15PM
Association between CV Outcomes, Diuretic Use and the a-Adducin Gene; Results from the International Verapamil SR-Trandolapril Study (INVEST) [36]
Tobias Gerhardt, Yan Gong, Amber L Beitselshees, Rhonda M Cooper-DelHoff, Julie A Johnson. (United States)

2:30PM
Non-Oncologic Use of Human Recombinant Erythropoietin in Hospitalized Patients [37]
Charles A Morris, Michael A Fischer, Wolfgang C Winkelmayer, Jerry Avorn. (United States)

2:45PM
ABCB1 G2677T/A and C3435T Polymorphisms and the Risk of Drug Induced Acute Agranulocytosis [38]
Frank Andersohn, Elisabeth Bronder, Andreas Klimpel, Edeltraut Garbe. (Germany)

3:00PM
Tumor Necrosis Factor-a Antagonist Use and Cancer in Patients with Rheumatoid Arthritis [39]
Soko Setoguchi, Daniel H Solomon, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Robert J Glynn, E Francis Cook, Greg Carney, Sebastian Schneeweiss. (United States)

3:15PM
Absence of an Interaction between the Angiotensin Converting Enzyme (ACE) Insertion-Deletion Polymorphism and Pravastatin on Cardiovascular Disease in High-Risk Hypertensives: The GenHAT Study [40]
Anke H Maitland-van der Zee, Eric Boerwinkle, Donna K Arnett, Barry R Davis, Catherine Leendeker-Foster, Michael B Miller, Olaf H Klungel, Charles E Ford, John E Eckfeldt. (Netherlands)

3:30-4:00PM
Break/Posters/Exhibits (PAV 4/5)
4:00 – 5:30PM

CONCURRENT SESSIONS

**SYMPOSIUM: Clinical Trial Simulation in Pharmacoepidemiology [43] (AUD 1)**
Sonia Hernández-Díaz, Wayne A Ray, Alexander M Walker, Miguel A Hernán. (United States)

**Pharmacovigilance: Contributed Papers (AUD 2)**
Moderators: Bruno Stricker & Marques Batel

**4:00PM**
Data Mining in the US FDA Adverse Event Reporting System (AERS); Depression/Suicidality and Unexpected Adverse Events with Anti Obesity Drugs [44]
F Patrick DeLisle, Kenneth Hornbuckle, Rebecca Noel. (United States)

**4:15PM**
Severe Necrotising Soft Tissue Infections and Necrotizing Fasciitis and NSAI: A Study in the French Pharmacovigilance Database [45]
Christelle Souyri, Pascale Olivier, Maryse Lapeyre-Mestre. (France)

**4:30PM**
Intervention To Improve Adverse Drug Event Reporting: A Cluster-Randomized Trial among Portuguese Physicians [46]
Teresa Herdeiro, Adolfo Figueiras, Manuela Pinto, Inês Vaz, Jorge Polónia. (Portugal)

**4:45PM**
A New Automatic Signal Detection Method in Pharmacovigilance: A Bayesian Multiple Comparisons Setting [47]
Ismail Ahmed, Françoise Haramburu, Annie Fournier, Frantz Thiessard, Bernard Bégaud, Pascale Tubert-Bitter. (France)

**5:00PM**
Evolution of Hospitalizations Related to Poisoning Events in Portugal [48]
José P Guerreiro, José Giria, Filipa Costa, Ermelindo Fontes, Ana C Miranda. (Portugal)

**5:15PM**
Are Inappropriate Medications the Major Cause of Adverse Drug Reactions in the Elderly? [49]
Marie-Laure Laroche, Jean-Pierre Charmes, Louis Merle. (France)

**WORKSHOP: Applications of Standardised MedDRA Queries (SMQs) in Drug Safety and Pharmacoepidemiology [62]**
Moderators: Gottfried Kreutz, Judith K Jones, Norbert Paeschke, Sabine Luik. (United States)

**WORKSHOP: Pharmacoepidemiology and Biotechnology Products [63]**
Joanna F Haas, Rhonda L Bohn, Kathryn Starzyk, Stella Blackburn, Bettie Voordouw, John Ferguson, Nancy Dreyer. (United States)

**Women’s Health: Contributed Papers (AUD 6)**
Moderators: Saad Shakir & Annlouise Assaf

**4:00PM**
Natural History of Newly Diagnosed Patients with Venous Thromboembolism [50]
Consuelo Huerta, Mary-Ann Wallander, Saga Johansson, Garcia Rodriguez. (Spain)

**4:15PM**
The Risk of Venous Thromboembolism (VTE) in Oral Contraceptives: A New Lesson [51]
Lothar A Heinemann, Anita Assmann, Juergen C Dinger. (Germany)

**4:30PM**
Factors Influencing Return to Fertility after Use of Oral Contraceptives [52]
Ilka Schellschmidt, Do Minh Thai, Sabine Moechner, Juergen C Dinger. (Germany)

**4:45PM**
Cyproterone Acetate + Ethinyloestradiol and the Risk of Depression [53]
Helen E Seaman, Julia Snowball, Corinne S de Vries. (United Kingdom)

**5:00PM**
Hormone Therapy Re-Initiation and First-Time Initiation by Type, Dose and Route, after the Women’s Health Initiative [54]
Katherine M Newton, Diana SM Buist, Onchee Yu, Cynthia L Hartsfield, Susan E Andrade, Feifei Wei, Maureen T Connelly, K Arnold Chan. (United States)

**5:15PM**
The European Active Surveillance Study on Oral Contraceptives (EURAS-OC): Final Results after More Than 130,000 WY of Observation [55]
Juergen C Dinger, Anita Assmann, Lothar A Heinemann. (Germany)
Infections/Pandemic Flu:
Contributed Papers  (AUD 8)

Moderators: Miles Braun, FISPE & Harry Seifert

4:00PM
Evaluating Reports of Fever after Diphtheria, Tetanus Toxoids, Acellular Pertussis, Hepatitis B, Inactivated Poliovirus Vaccine Combined (DTaPHE) from the U.S. Vaccine Adverse Event Reporting System (VAERS) [56]
Soju Chang, John Iskander, Karen Farizo, M Miles Braun, Robert Ball. (United States)

4:15PM
An Evaluation of the Effects of Gatifloxacin on Glucose Homeostasis [57]
Ahunna Onyenwenyi, Almut Winterstein, Randy Hatton. (United States)

4:30PM
Antibacterial Drugs and the Risk of Infection with Methicillin Resistant Staphylococcus Aureus (MRSA) in the Community [58]
V Schneider, S Dial, J A Delaney, A Dascal, S Suissa. (Canada)

4:45PM
Anti-TNF-alpha Therapy and the Risk of Severe Bacterial Infections [59]
Sebastian Schneeweiss, Soko Setoguchi, Michael E Weinblatt, Jeffrey N Katz, Jerry Avorn, Paul E Sax, Raia Levin, Daniel H Solomon. (United States)

5:00PM
Annual Influenza Vaccination and Risk of Sudden Cardiac Death in Community Dwelling Elderly Persons [60]
Bettie CG Voordouw, Sabine SJM Straus, Miriam CJM Sturkenboom, Jeanne P Dieleman, Theo Stijnen, Johan van der Lei, Bruno HCh Stricker. (Netherlands)

5:15PM
Quinolone Use and the Risk of Community-Acquired Clostridium difficile in the United Kingdom [61]
J A Delaney, Sandra Dial, Alan N Barkun, Samy Suissa. (Canada)

5:30-6:30PM
ISPE Council Meetings
* Open to all participants.

Academic Council  (AUD 2)
Industry Council  (AUD 6)
Government Council  (AUD 8)
EuroDURG Executive Committee  (Room 1.1)

6:30-8:30PM
EXTERNALLY FUNDED SYMPOSIUM*

GPRD Users Group Meeting  (Hotel Vila Gale Opera)
* Open to all participants. Not part of the ICPE Scientific Program.
This symposium provides an opportunity to learn about the latest developments in GPRD, including new data linkages, the new possibility of conducting randomized studies within GPRD, and a novel approach in risk-benefit assessment. A canapé reception to follow.

PDS Editorial Board  (Pestana Palace)
(By invitation)

7:30-10:00PM
Student Social Event
Check bulletin board at Registration Desk for details.
Open to all students.
Organized by the ISPE Student Council
AGENDA | Saturday, August 26

JOINT ISPE–EURODURG DAY

7:30-8:30AM
► Special Interest Group – Drug Utilization (Hotel Vila Gale Opera)
  *Open to all participants.

8:00-9:00AM
► Poster Session B Set-up (PAV 4)

8:00-5:00PM
► Exhibits (PAV 5)

8:00-6:00PM
► Registration (Registration Desk/Ground Floor/Congress Centre)

9:00-10:30AM

PLENARY SESSION

► Balancing Patient Safety and Pharmaceutical Innovation: Fostering the Lisbon Objectives (AUD 1)
  Moderator: Fernard Sauer

  Vasco de Jesus Maria, Is ‘Lisbon’ Still Driving the EU Medicines Policy Agenda?
  Albert van der Zeijden, Are Patients Happy with so much Focus on Safety?
  Susana Perez-Gutthann, FISPE, How is Industry Balancing Innovation and Patient Safety?

10:30-11:00AM
► Break/Posters/Exhibits (PAV 4/5)
I want to share my expertise.

You can at AstraZeneca. As a global pharmaceutical industry leader, AstraZeneca has created a work environment that cultivates talent and rewards success. We offer competitive compensation and benefits, a commitment to professional development, and the opportunity to be part of an exciting, dynamic workplace.

Among our many awards we have been recognized in 2005 as one of the Top Employers by Science magazine and one of the 100 Best Employers for Working Mothers by Working Mother magazine. AstraZeneca embraces diversity, innovation and creativity — pushing the boundaries of conventional thought to make our ideas come to life.

To apply, please submit your resume via email to opportunities.mailbox@astraZeneca.com and reference source code 11436635 in the Subject line.

We are an equal opportunity employer.

We have the following United States based career opportunity available in our Wilmington, Delaware location.

Assoc. Director/Director/Sr. Director, Epidemiology

Working within the Medical Science group, this individual will provide epidemiology expertise for one of several therapeutic areas. Will work with senior staff on study design, analysis, data interpretation, and reporting functions related to clinical trials; ensure clinical studies operate with the highest safety standards and are in compliance with all GCP and regulatory requirements; perform in-depth epidemiological literature reviews; and initiate and monitor epidemiological research conducted by external scientific groups.

Physicians (Epidemiologists) must have two or more years of drug development experience within a related industry or in academia. Significant experience designing clinical trials and interpreting results, and a comprehensive understanding of biostatistics and safety reporting. Scientists (PhD) in epidemiology should possess at least 5 years' experience as an epidemiologist in a healthcare environment and sustained productivity in epidemiological research relevant to drug discovery.
11:00 – 12:30 PM
CONCURRENT SESSIONS

ISPE-EuroDURG SYMPOSIUM (AUD 1)
Global Assessment of the Contribution of Drug Utilization Research to Public Health
Co-Chairs: Frank May, FISPE & Robert Vander Stichele
Speakers: Flora Haaijer-Ruskamp, Europe; Richard Laing, Developing World; Junichi Kawakami, Japan; Jerry Avorn, FISPE, US/Canada; Lynn Weekes, Australia

Methods: Contributed Papers (AUD 2)
Moderators: Tjeerd van Staa & Alexander M. Walker, FISPE

11:00AM
Mixed Effect Poisson Regression with Empirical Bayes Random Effect Estimation: Application to Opioid Analgesic Abuse in the US [64]
William Irish, Meredith Smith, Jianmin Wang, Rick Dart. (United States)

11:15AM
Pharmacologic Interventions for the Prevention of Alzheimer’s Disease: An Example of Reverse Protopathic Bias [65]
Linda E Levesque, JAC Delaney, Mahyar Etminan, Samy Suissa. (Canada)

11:30AM
Randomized Experiments Versus Observational Studies? The Case of Antiretroviral Therapy and AIDS [66]
Miguel A Hernan, Stephen R Cole. (United States)

11:45AM
Nested Case-Control Validation of Results of the Zelnorm™ Epidemiological Study [67]
John D Seeger, Najat Ziyadeh, Fabio Lievano, Elena Rivero, David L Earnest, Michael Shetzline, William Holden, Alexander M Walker. (United States)

12:00 PM
Stratified Case-Cohort Design in Pharmacoepidemiological Studies [68]
Akira Wakana, Kiyoshi Kubota. (Japan)

12:15PM
Risk Adjusted Sequential and Longitudinal Monitoring Drug Performance Using GPRD [69]
Mark L Ma, Kenneth Hornbuckle, Simon Voss, Xiao Yu. (United States)

WORKSHOP: Willingness To Accept Risk-Benefit Tradeoffs: Pharmacoepidemiology Meets Preference Measurement [77]
(AUD 4)
F Reed Johnson, Teresa Kauf, Elizabeth B Andrews. (United States)

Antipsychotics: Contributed Papers (AUD 6)
Moderators: Antoine Egberts & Julie Zito

11:00AM
Antipsychotic Use and the Development of Cardiovascular Conditions in the Elderly [70]
Philip S Wang, Sebastian Schneeweiss, Soko Setoguchi, Jerry Avorn, Helen Mogun, Niteesh Choudhry, M Alan Brookhart. (United States)

11:15AM
The Use of Atypical and Conventional Antipsychotics and the Risk of Acute Pancreatitis: A Population-Based Case-Control Study [71]
Christiane Gasse, Jacob Jacobsen, Mette Nørgaard, Preben B Mortensen, Søren P Johnsen, Henrik T Sørensen. (Denmark)

11:30AM
Risk of Stroke during Treatment with Atypical and Conventional Antipsychotics: A Population-Based Study in the UK [72]
Annalisa Rubino, Stephen J Evans, Liam Smeeth. (United Kingdom)

11:45AM
Use of Antipsychotics and Risk of Hip/Femur Fractures: A Population Based Case-Control Study [73]
Sander Pouwels, Frank de Vries, Antoine CG Egberts, Bert GM Leufkens, Tjeerd P van Staa. (Netherlands)

12:00PM
Early Effects of an FDA Advisory Regarding Antipsychotics Medications on U.S. Medicaid Prior Authorization Programs [74]
Jennifer Polinski, Michael Fischer, Amber Servi, Elizabeth Robinson, Philip Wang. (United States)

12:15PM
Anti-Psychotic Drugs and the Risk of Acute Urinary Retention [75]
Katia MC Verhamme, Jeanne P Dieleman, Marc Van Wijk, Johan van der Lei, Ruud Bosch, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)
19

SYMPOSIUM: Increased Transparency To Improve the Credibility of Pharmacoepidemiologic Studies Submitted to Regulatory Agencies and Journals? [76] (AUD 8)
Michael N Cook, Robert C Nelson, Sean Hennessy, Julie E Buring. (United States)

12:30-2:00PM
Lunch/Poster Session B/Exhibits
(PAV 4/5)

12:30-2:00PM
EuroDURG Poster Walk (PAV 4)
*Open to all participants.

ISPE Committee Meetings
Lunches will be available in meeting rooms.
*Open to all participants.

Development (Room 1.08)
Membership (Room 1.07)
Global Development (Room 1.06)
Publications (Room 1.05)
AGENDA  |  Saturday, August 26

2:00–3:30PM

ANNUAL MEETING & AWARDS CEREMONY

Open to all participants. (AUD 1)

Induction of ISPE Fellows (FISPE)

Gerald A. Faich, FISPE, Chair, Fellowship & Awards Committee and ISPE Immediate Past President

- Inductees:
  - Syed Rizwanuddin Ahmad, FISPE
  - Miles Braun, FISPE
  - Thomas R. Einarson, FISPE
  - Til Stürmer, FISPE
  - Suzanne L. West, FISPE

ISPE-PDS Prizes

Presented by Brian L. Strom, FISPE, Regional Editor for the Americas, *Pharmacoepidemiology & Drug Safety*

Giovanni Corrao, Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials

Hilde Tobi, Small proportions: what to report for confidence

Nancy S. Breekveldt, Postma Selective prescribing of atypical antipsychotics

Dustin D. French, Benzodiazepines and injury: a risk adjusted model

Robert J. Cluxton Jr, Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio Medicaid program

ISPE Distinguished Service Award

Presented by Sean Hennessy, FISPE

- Recipient: Frank May, FISPE

ISPE Sustained Scientific Excellence Award

Presented by Gerald A. Faich, FISPE

- Recipient: Brian L. Strom, FISPE
- Address by: Brian L. Strom, FISPE
  The Lessons of Experience: Selected Tidbits from a Mid-Career Academic Pharmacoepidemiologist
CONCURRENT SESSIONS

SYMPOSIUM: How Can Prescribing Quality Indicators Improve Public Health [78] (AUD 1)
Flora M Haaijer-Ruskamp, Tony J Avery, Jerry Avorn, Bjorn Wettermark.
(Netherlands)

Propensity Scores: Contributed Papers (AUD 2)
Moderators: Kenneth J. Rothman, FISPE & Alejandro Arana, FISPE

4:00PM
The Limiting Role of the C-Statistic in the Use of Propensity Scores: Evidence from Simulation and Real Life Data [79]
Maurille A Feudjo-Tepie, Victor A Kiri. (United Kingdom)

4:15PM
Adjustment for Multiple Cardiovascular Risk Factors with a Summary Risk Score [80]
Patrick G Arbogast, Hua Ding, Wayne A Ray. (United States)

4:30PM
Estimation and Use of Propensity Scores in Case-Control and Case-Cohort Studies [81]
Roger Mansson, Sean Hennessy, Marshall M Joffe. (United States)

4:45PM
Validation of Propensity Score Matching of Ethinyl Estradiol / Drospirenone and Other Oral Contraceptive Initiators [82]
P Mona Eng, John D Seeger, Jeanne Loughlin, C Robin Clifford, Sherry Mentor, Alexander M Walker. (United States)

5:00PM
Comparison of Performance of Propensity Score Calibration (PSC) and Multiple Imputation (MI) To Control for Unmeasured Confounding Using an Internal Validation Study [83]
Til Stürmer, Sebastian Schneeweiss, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)

5:15PM
Bayesian Propensity Score Analysis for Observational Data [84]
Lawrence C McCandless, Paul Gustafson, Peter C Austin. (Canada)

WORKSHOP: To “p” or Not To “p”? How Do ISPE Members Feel about p-Values and Statistical Testing: An ISPE Public Policy Forum [92] (AUD 4)
Elisabeth B Andrews, Susana Perez-Gutthann. (United States)

Antidepressants: Contributed Papers (AUD 6)
Moderators: Jan Willem van der Velden, FISPE & Thomas MacDonald, FISPE

4:00PM
Risk of Suicide during Venlafaxine and Comparator Antidepressants Treatment [85]
Annalisa Rubino, Neil Roskell, Pat Tennis, Daniel Mines, Scott Weich, Elizabeth Andrews. (United Kingdom)

4:15PM
Tricyclic Antidepressants and the Risk of Esophagitis [86]
Eva M van Soest, Jeanne D Dieleman, Peter D Siersema, Miriam JCM Sturkenboom, Ernst J Kuipers. (Netherlands)

4:30PM
The Risk of Fractures in Patients Currently or Previously Using Lithium [87]
Ingeborg Wilting, Frank de Vries, Brah MKS Thio, Cyrus Cooper, Eibert R Heerdink, Hubert GM Leufkens, Willem A Nolen, Antoine CG Egberts, Tjeerd P van Staar. (Netherlands)

4:45PM
Selective Serotonine Reuptake Inhibitors and Risk of Acute Pancreatitis: A Population-Based Case-Control Study [88]
Mette Nørgaard, Jacob Jacobsen, Christiane Gasse, Lars Pedersen, Preben B Mortensen, Henrik T Sørensen. (Denmark)

5:00PM
The Association between Antidepressant Use and Hypoglycemia in Diabetic Patients: A Nested Case-Control Study [89]
Hieronymus J Derijks, Fred HP De Koning, Eibert R Heerdink, Robert Janknegt, Olaf H Klungel, Antoine CG Egberts. (Netherlands)

5:15PM
Bayesian Propensity Score Analysis for Observational Data [84]
A Comparison of Patient Profiles of SSRI and SNRI Users [90]
Li Wei, Thomas M MacDonald. (United Kingdom)

continued on next page
AGENDA | Saturday, August 26

4:00 - 5:30PM
 opener
 Syed R Ahmad, Gerald DalPan, June M Raine, Richard Hill, Christopher D Corsico. (United States)

5:30-6:30PM
 opener
 Special Interest Group - Health Services Research & Education (AUD 4)
 Open to all participants

 opener
 2007 Scientific Program Committee Meeting (Room 1.08)
 Jean-Pierre Gregoire, Chair
 Open to ISPE members.

7:30-11:30PM
 Evening at the Pateo Alfacinha
 Sponsored by i3 Drug Safety

From the late 1800’s working people flooded into Lisbon looking for a better life. They build a new sort of town, squeezing many families into small areas, with as much privacy as possible, and with a country flavour Lisbon has never lost. Pateo Alfacinha has restored a pateo with a breath of village life and community, with its many rooms and floors linked together with the wisdom and charm of the original, and ironwork and tiles from old buildings. You will experience Portuguese music, food and wine, cheeses and other tidbits. Here you can make contact with Lisbon of hundreds of years ago. Limited seating - registration required.

Admission is by ticket only. Buses will shuttle from the Congress Centre and (ISPE) hotels to the Pateo Alfacinha beginning at 7:00PM. The last bus will depart from the Pateo Alfacinha at 11:30PM, passing by all hotels.

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that brings population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:
• Analyzing the occurrence and distribution of diseases, including underlying disease process
• Determining the burden of illness and unmet medical need
• Exploring traditional and new risk factors for diseases
• Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug use and adverse events
• Detecting opportunities for possible new drug uses and new paths of drug development
• Understanding how genes influence disease etiology and drug safety and effectiveness

Please visit our booth at the 22nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management or our website at http://epidemiology.gsk.com, to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Together we can make life better.

GlaxoSmithKline
Are you interested in registries for safety and effectiveness?

Come hear Dr. Nancy Dreyer speak on Friday, August 25 at 4:00 pm.

WEB-BASED REGISTRIES

RAPID DEVELOPMENT OF EVIDENCE

Nancy A. Dreyer, MPH, PhD is Chief of Scientific Affairs for OUTCOME, a recognized leader in post-approval strategy.

OUTCOME has designed, developed and managed more than 70 post-approval studies and registries through prospective data collection with our web-based technology and integrated IVRS, PDA and paper options.

OUTCOME’s studies include many of the largest and most well-recognized programs for disease outcomes and safety/risk management. OUTCOME is also a leader in Quality Improvement Programs and in 2004 received the Innovation Award from the Department of Health and Human Services.

With tens of thousands of sites and more than 2 million patients enrolled in studies powered by OUTCOME, OUTCOME provides the most widely used solutions in the post-approval market.

OUTCOME
POST-MARKETING EXCELLENCE

www.outcome.com  888-526-6700  info@outcome.com
AGENDA | Sunday, August 27

8:00–9:00AM

Poster Session C Set-up (PAV 4)

8:00–1:45PM

Exhibits (PAV 5)

8:00–4:00PM

Speaker Ready Room/AV (Rooms 1.09 + 1.14)

8:00–5:00PM

Registration (Registration Desk/Ground Floor/Congress Centre)

9:00–10:30AM

CONCURRENT SESSIONS

SYMPOSIUM: Large Simple Trials To Evaluate the Safety and Effectiveness of Medicines [93] (AUD 1)
Robert Reynolds, Allen Mitchell, Sybil Eng, Tom MacDonald, Gerald Faich. (United States)

Pills and Policy: Contributed Papers (AUD 2)
Moderators: Morten Andersen & Lokje de Jong van den Berg

9:00AM

Equal Access to Treatment? Population-Based Follow-Up of Drugs Dispensed to Patients with Acute Myocardial Infarction in Sweden [94]
Gunilla Ringbäck Weitoft, Örjan Ericsson, Emil Löfroth, Måns Rosén. (Sweden)

9:15AM

Impact of Prior Authorization on Use of Angiotensin Receptor Blockers in U.S. Medicaid Programs [95]
Michael A Fischer, Niteesh K Choudhry, Wolfgang C Winkelmayer. (United States)

9:30AM

Impact of Restrictive Access to Clopidogrel Following Coronary Stent Implantation on Patient Health Outcomes [96]
Odile Sheehy, Jacques LeLorier, Stéphane Rinftret. (Canada)

9:45AM

Assessment of Analgesic Treatment Switch Patterns Post-Rofecoxib Withdrawal [97]
Myrthe PP Sukel, Wim G Goettisch, Susan E Borgevre, Connie Chen, Piotr Kramarz, Herve Lilliu, Ron MC Herings. (Netherlands)

10:00AM

What Therapies Have Replaced Rofecoxib? [98]
Mary Teeling, Kathleen Bennett, John Feely. (Ireland)

10:15AM

Rapid Monitoring of Changes in Drug Use Following Drug Policy Changes [99]
Colin R Dormuth, Sebastian Schneeweiss. (Canada)

9:00AM

Migraine and the Risk of Stroke, Asthma or Death in the United Kingdom [112]
Claudia Becker, Gunnar Brobert, Per Almqvist, Saga Johansson, Susan S Jick, Christoph R Meier. (Switzerland)

9:15AM

The Impact of Visual Impairment on the Risk of Depression and Mortality in the Quebec Community-Dwelling Elderly Population [113]
Yola Moride, Marie Tournier, Ducruet Thierry, Sophie Rochon, Andriy Moshyk. (Canada)

9:30AM

Thiazolidinedione Use Is Associated with Lower Incidence of Alzheimer’s Disease [560]
Donald R Miller, Benjamin G Fincke, Julie E Davidson, John G Weil. (United States)

9:45AM

Amyloid b42-Level Lowering Non-Steroidal Anti-Inflammatory Drugs and the Risk of Alzheimer’s Disease [115]
Mendel DM Haag, Marieke van Oijen, Frank Jan de Jong, Albert Hofman, Theo Stijnen, Bruno H Ch Stricker, Monique MB Breteler. (Netherlands)

10:00AM

Overuse of Triptans and Ergotamine and the Risk of Vasoconstrictive Complications [116]
Elisabeth A Wammes-van der Heijden, Hamid Rahimtoola, Hubert GM Leufkens, Cees C Tijssen, Antoine CG Egberts. (Netherlands)

10:15AM

The Concurrent Use of Cholinesterase Inhibitors and Contraindicated Medications in Patients with Alzheimer’s Disease [117]
Alison L Supina, Amuah E Joseph, Maxwell J Colleen, Hogan B David. (Canada)
Stat Ins or Stat OUT: Contributed Papers (AUD 6)
Moderators: Kate Lapane, FISPE & Olaf Klungel

9:00AM
Is Statin Therapy Associated with a Decreased Risk for Bleeding in Patients with Chronic Atrial Fibrillation Who Are Receiving Warfarin? A Population-Based Nested Case-Control Study [100]
James D Douketis, Magda Melo, Chaim Bell, Muhammad M Mamdani. (Canada)

9:15AM
Statin Therapy and Reduced Risk of Pneumonia in Elderly Patients with Diabetes [101]
Ewoudt MW van de Garde, Eelko Hak, Patrick C Souverein, Arno W Hoes, Jules MM van den Bosch, Hubert GM Leufkens. (Netherlands)

9:30AM
Lipid-Modifying Therapy and attainment of Cholesterol Goals in Europe: The Return on Expenditure Achieved for Lipid Therapy (REALITY) Study. [102]
Eric Van Ganse, Thierry Souchet, Laurent Laforest, Evo Alemao, Glenn Davies, Stephen Gutkin, Don Yin. (France)

9:45AM
Are All Statins Created Equal? An Analysis of Acute Coronary Syndrome Patients in Medicare [103]
Niteesh K Choudhry, Raisa Levin, Wolfgang C Winkelmayre. (United States)

10:00AM
The Effect of Statins on Urinary Albumin Excretion (UAE) and Glomerular Filtration Rate (GFR): An RCT and an Observational Cohort Study [104]
Jarir Atthobari, Auke H Brantsma, Ron T Gansevoort, Sipke T Visser, Paul E de Jong, Lolkje TW de Jong-van den Berg. (Netherlands)

10:15AM
Statin Use in Canada: Association with Lifestyle Risk Factors and Pre-Existing CVD or Diabetes [105]
C Ineke Neutel, Norm RC Campbell. (Canada)

Adherence and Switching:
Contributed Papers (AUD 8)
Moderators: Judith Jones, FISPE & John Urquhart, FIPSE

9:00AM
Impact of Once-Weekly Bisphosphonates on Persistence Rate and Adherence Level with Osteoporosis Therapies for Secondary Prevention [106]
Julie Blouin, Alice Dragomir, Louis-Georges Ste-Marie, Julio Cesar Fernandes, Sylvie Perreault. (Canada)

9:15AM
Evaluation of Treatment Switching Patterns in Depression: A GPRD-Based Study [107]
Delphine Saragossi, Sebastien Bineau, Nicolas Despiegel, Dominique Milea, Mondher Toumi, Patrice Verpillat. (France)

9:30AM
Time to Insulin after Failure of Oral Antidiabetic Therapy in Type 2 Diabetes: A UK Population-Based Analysis [108]
Annalisa Rubino, Lisa McQuay, Marion Kvasz, Pat Tennis. (United Kingdom)

9:45AM
Changes in Antihypertensive Drug Use Following Educational Interventions in Primary Care [109]
Sheena O’Riordan, Fiona E Horn, Judith M Mackson, Sonia E Wutzke, John Mandryk, Lynn M Weekes. (Australia)

10:00AM
Adherence to Statin Therapy under Drug Cost-Sharing in Patients with and without Acute MI: A Population-Based Natural Experiment [110]
Sebastian Schneeweiss, Mandy Patrick, Malcolm Maclure, Colin Dormuth, Robert Glynn. (United States)

10:15AM
The Effects of Adherence on Anticoagulation Control with Warfarin [111]
Stephen E Kimmel, Zhen Chen, Maureen Price, Catherine S Parker, Joshua P Metlay, Jason D Christie, Colleen M Brensinger, Craig W Newcomb, Frederick F Samaha, Robert Gross. (United States)

10:30-11:00AM
Break/Posters/Exhibits (PAV 4/5)
## AGENDA  |  Sunday, August 27

### 11:00 - 12:30 PM

## CONCURRENT SESSIONS

### SYMPOSIUM: Do Exclusion Criteria in Pharmacoepidemiological Studies Matter? [118] (AUD 1)

- Michael J Perrio, Patrick C Waller, Thomas M MacDonald, Kenneth J Rothman, Saad AW Shakir. (United Kingdom)

### Drug Utilization Research, Methods, Findings and Implications: Contributed Papers (AUD 2)

**Moderators:** Lynn A. Bosco & Ulf Bergman, FISPE

- **11:00AM**
  
  Differences in Secondary Medical Prevention among Danish Patients with Peripheral Arterial Disease and Myocardial Infarction: A Population-Based Follow-Up Study [119]
  
  Christiane Gasse, Jacob Jacobsen, Henrik T Sørensen, Erik B Schmidt, Anders C Larsen, Niels Johansen, Jørgen Videbæk, Søren P Johnsen. (Denmark)

- **11:15AM**
  
  Cardioprotective Drug Treatment of Elderly Type 2 Diabetics in Quebec: A Population-Based Utilization Review [120]
  
  Caroline Sirois, Jocelyne Moisan, Jean-Pierre Gregoire. (Canada)

- **11:30AM**
  
  Temporal Trends in Cardiovascular Drug Use after Myocardial Infarction in the Elderly [121]
  
  Soko Setoguchi, Jerry Avorn, Robert J Glynn, Wolfgang C Winkelmayer. (United States)

- **11:45AM**
  
  Factors Associated with COX-2 Usage Patterns: A Multinomial Analysis in the CADEUS Study [122]
  
  Jeremy Jove, Jacques Benichou, Fanny Depont, Cecile Droz, Michel Amouretti, Patrick Blin, Nicholas Moore, Annie Fourrier, The CADEUS Study Team. (France)

- **12:00PM**
  
  Face to Face Interaction between Pharmaceutical Sales Representatives and General Practitioners: Impact on Prescribing Patterns [123]
  
  Jens Sondergaard, Kirstin Vach, Jakob Kraagstrup, Morten Andersen. (Denmark)

- **12:15PM**
  
  Comparison of Patient Interviews and Computerized Database for Determination of Drug Exposure in Pharmacoepidemiology: Data from the “Three-City” (3C) Study [124]
  
  Pernelle Noize, Nicholas Moore, Nathalie Lechevallier-Michel, Annie Fourrier-Reglat, The 3C Study Group. (France)

### Public Health Implications: Contributed Papers (AUD 3 & 4)

**Moderator:** M Levy

- **11:00AM**
  
  Clinical Consequences of Drug Benefit Limits [137]
  
  John Hsu, Maggie Price, Richard Brand, Joseph Newhouse, Joseph Selby, Rita Hui, Jie Huang, Vicki Fung, Bruce Fireman. (United States)

- **11:15AM**
  
  A Database for Pharmacoepidemiologic Research in Portugal [138]
  
  Zilda Mendes, José Pedro Guerreiro, Sofia Crisóstomo. (Portugal)

- **11:30AM**
  
  Patterns of Medication Use in U.S. Adults and Children, 2005: A Report from the Slone Survey [139]
  
  David W Kaufman, Judith P Kelly, Lynn Rosenberg, Theresa E Anderson, Katherine Kelly, Allen A Mitchell. (United States)

- **11:45AM**
  
  Patient, Physician, Pharmacy and Pharmacy Benefit Design Factors Related to Generic Medication Use [140]
  
  William H Shrank, Margaret Stedman, Susan Ettner, Dee Delapp, June Dirstein, Alan Brookhart, Michael Fischer, Jerry Avorn, Steven Asch. (United States)

- **12:00PM**
  
  Determinants of Hormone Replacement Therapy in Portuguese Women [141]
  
  Raquel Lucas, Henrique Barros. (Portugal)

- **12:15PM**
  
  Effect of Restricted Access to Clopidogrel on Patient Health Outcomes Following Cerebrovascular Event in the Elderly [142]
  
  Odile Sheehy, Stéphane Rinfret, Élisabeth Leroux, Jacques LeLorier. (Canada)
COX-2 and Cardiovascular Events: Contributed Papers (AUD 6)

Moderators: Mirjam CJM Sturkenboom & Jacques LeLorier, FISPE

11:00AM
Association between Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs and Acute Myocardial Infarction in the General Practice Research Database: Preliminary Findings [125]
Tarek A Hammad, David Graham, Judy Staffa, Cynthia Kornegay, Gerald Dal Pan. (United States)

11:15AM
COX-2 Selective and Non-Selective NSAIDs and the Risk of Acute Myocardial Infarction [126]
Frank Andersohn, Samy Suissa, Edeltraut Garbe. (Germany)

11:30AM
Cox-2 Inhibitors, Other NSAIDs, and the Risk of Myocardial Infarction in Three Populations in Three Countries (UK, Canada, and the US) [127]
Michael A Lewis, Donald R Miller, Elham Rahme, Dörthe Kühn-Habich, Fran Cunningham, Amir A Tahami Monfared, David W Kaufman, Lynn Rosenberg, Jacques LeLorier. (Germany)

11:45AM
Variability of Cardiovascular Risk in Observational Studies of Nonsteroidal Antiinflammatory Drugs (NSAIDs): The Role of Calendar Time Bias [128]
Linda L Levesque, James M Brophy, Bin Zhang. (Canada)
* Student Award – Best Methods Abstract

12:00PM
Concomitant Aspirin Use Reduces Acute Myocardial Infarction Risk in Cyclooxygenase-2 Selective and Non-Selective Nonsteroidal Anti-Inflammatory Drug Users [129]
David J Graham, Gurkirpal Singh, Huijian Wang, Alka Mithal, George Triadafilopoulos. (United States)

12:15PM
Risks and Benefits of COX-2 Inhibitors Versus Non-Selective NSAIDs: Does Their Cardiovascular Risk Exceed Their Gastrointestinal Benefit? [130]
Elham Rahme, Hacene Nedjar. (Canada)
Cancer Risk, Prevention and Treatment: Contributed Papers

Moderators: Nuno Lunet & Susan Sacks, FISPE

11:00AM
Treatment-Related Risk Factors for Premature Menopause Following Hodgkin’s Lymphoma [131]
Marie L De Bruin, Jeannine Huisbrink, Berthe M Aleman, Floor E van Leeuwen.
(Netherlands)

11:15AM
The Risk of Cancer with Antidiabetic Agents: Evidence from Clinical Trial and Observational Data [132]
Carol E Koro, Susan A Oliveria, Marianne Ulcickas Yood, Margaret O Sowell, Monika Stender. (United States)

11:30AM
The Effect of Warfarin Use on the Risk of Urogenital Cancer [133]
Vicky Tagalakis, Hani Tamim, Jean-Paul Collet, Susan R Kahn, Mark Blostein, James A Hanley. (Canada)

11:45AM
Long-Term NSAID Use and CYP2C9 Variant Alleles Protect Against Colorectal Cancer [134]
Claire Siemes, Loes E Visser, Jan-Willem W Coebergh, Ron HN van Schaik, Albert Hofman, Huib AP Pols, Bruno HCH Stricker. (Netherlands)

12:00PM
Risk of Lymphoma Following Exposure to Calcineurin Inhibitors and Topical Steroids in Patients with Atopic Dermatitis [135]
Felix M Arellano, Charles E Wentworth, Alejandro Arana, Carlos Fernandez, Carle Paul, Felix M Arellano, Carle Paul. (United States)

12:15PM
History of Depression Predicts Early Discontinuation of Tamoxifen [136]
Thomas I Barron, Kathleen Bennett, John Feely. (Ireland)

12:30-2:00PM
Lunch/Poster Session C/Exhibits

1:45PM
ISPE Board of Directors Luncheon
(Hotel Vila Gale Opera)
-By Invitation

3:00-4:30pm
INVITED PLENARY (AUD 1)
Henrique de Barros, Managing Drug Risks in Public Health

3:00-4:30pm
More Science and Less Regulatory Compliance in Postmarketing Safety
Chair: Brian Strom, FISPE
June Raine, Is Science Driving Regulatory Action. or ...??
David Graham, Can We Respond to All Safety Issues with a Series of Formal Pharmacopei Studies?
Andy Stergachis, FISPE, The IOM Report: Can We Expect More Science?

4:30-5:00PM
The Final Word (PAV 1)
Jean-Pierre Gregoire,
Chair, 2007 Scientific Program Committee

5:00PM
Adjournment of ICPE 2006